Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 28;10:18515. doi: 10.1038/s41598-020-75598-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Anti-cancer effect of salinomycin in melanoma cell lines. (a) IC₅₀ of eight melanoma cell lines were detected by MTS assay after treated with Sal at the indicated concentrations (0–40 μM) and calculated by GraphPad Prism. (b) SK-Mel-19 cells were treated with different concentrations of Sal for 72 h, and cell viability was tested by MTS assay. (c) Changes in the morphology of SK-Mel-19 cells. Cells after treatment with 1.0 μM Sal for the indicated period of time were examined by phase-contrast microscopy (magnification, × 200). (d) Tumor volume growth curve of five groups. (e) Comparison of the relative tumor proliferation rate V_Treatment/V_Control of five groups (n = 8). (f) The excised tumors were weighed at the end point. The scatter diagram of tumor weight was shown. (g) Tumor weight inhibition rate of five groups were calculated (n = 8). (*p < 0.05; **p < 0.01; ***p < 0.001 vs control).